WO2002088721A3 - Biopolymer marker having a molecular weight of 1206 daltons - Google Patents

Biopolymer marker having a molecular weight of 1206 daltons Download PDF

Info

Publication number
WO2002088721A3
WO2002088721A3 PCT/CA2002/000609 CA0200609W WO02088721A3 WO 2002088721 A3 WO2002088721 A3 WO 2002088721A3 CA 0200609 W CA0200609 W CA 0200609W WO 02088721 A3 WO02088721 A3 WO 02088721A3
Authority
WO
WIPO (PCT)
Prior art keywords
daltons
molecular weight
absence
ability
presence
Prior art date
Application number
PCT/CA2002/000609
Other languages
French (fr)
Other versions
WO2002088721A2 (en
Inventor
George Jackowski
Brad Thatcher
Tammy Vrees
Jason Yantha
John Marshall
Original Assignee
Syn X Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US09/845,725 priority Critical
Priority to US09/845,725 priority patent/US6627608B2/en
Application filed by Syn X Pharma Inc filed Critical Syn X Pharma Inc
Publication of WO2002088721A2 publication Critical patent/WO2002088721A2/en
Publication of WO2002088721A3 publication Critical patent/WO2002088721A3/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/24Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/25Chemistry: analytical and immunological testing including sample preparation

Abstract

The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or absence of said biopolymer.
PCT/CA2002/000609 2001-04-30 2002-04-26 Biopolymer marker having a molecular weight of 1206 daltons WO2002088721A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US09/845,725 2001-04-30
US09/845,725 US6627608B2 (en) 2001-04-30 2001-04-30 Biopolymer marker indicative of disease state having a molecular weight of 1206 daltons

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2002257402A AU2002257402A1 (en) 2001-04-30 2002-04-26 Biopolymer marker having a molecular weight of 1206 daltons

Publications (2)

Publication Number Publication Date
WO2002088721A2 WO2002088721A2 (en) 2002-11-07
WO2002088721A3 true WO2002088721A3 (en) 2002-12-27

Family

ID=25295944

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2002/000609 WO2002088721A2 (en) 2001-04-30 2002-04-26 Biopolymer marker having a molecular weight of 1206 daltons

Country Status (3)

Country Link
US (1) US6627608B2 (en)
AU (1) AU2002257402A1 (en)
WO (1) WO2002088721A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7008800B2 (en) * 2001-04-30 2006-03-07 Artemis Proteomics, Ltd. Biopolymer marker indicative of disease state having a molecular weight of 1077 daltons
US20040236603A1 (en) * 2003-05-22 2004-11-25 Biospect, Inc. System of analyzing complex mixtures of biological and other fluids to identify biological state information
US7425700B2 (en) * 2003-05-22 2008-09-16 Stults John T Systems and methods for discovery and analysis of markers
US20050244973A1 (en) * 2004-04-29 2005-11-03 Predicant Biosciences, Inc. Biological patterns for diagnosis and treatment of cancer
US20120001065A1 (en) * 2009-03-18 2012-01-05 Mayo Foundation for Medical Education and Rsearch Evaluating renal function

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5538897A (en) * 1994-03-14 1996-07-23 University Of Washington Use of mass spectrometry fragmentation patterns of peptides to identify amino acid sequences in databases
US5817768A (en) * 1995-06-07 1998-10-06 The New York Blood Center, Inc. Monospecific antibodies against a subunit of fibrinogen
WO2000009562A1 (en) * 1998-08-12 2000-02-24 The New York Blood Center, Inc. Novel cleaved fragments of fibrinogen
WO2000049410A2 (en) * 1999-02-16 2000-08-24 The Government Of The United States Of America, As Represented By The Secretary Department Of Health & Human Services, The National Institutes Of Health Lcm (laser capture microdissection) for cellular protein analysis
WO2001005422A2 (en) * 1999-07-15 2001-01-25 Biomerieux Stelhys Use of a polypeptide for detecting, preventing or treating a pathological condition associated with a degenerative, neurological or autoimmune disease
WO2001075454A2 (en) * 2000-04-03 2001-10-11 Oxford Glycosciences (Uk) Ltd. Diagnosis and treatment of alzheimer's disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3809504C1 (en) 1988-03-22 1989-09-21 Bruker - Franzen Analytik Gmbh, 2800 Bremen, De
WO1990014148A1 (en) 1989-05-19 1990-11-29 Fenn John B Multiply charged ions and a method for determining the molecular weight of large molecules
US6020208A (en) 1994-05-27 2000-02-01 Baylor College Of Medicine Systems for surface-enhanced affinity capture for desorption and detection of analytes
US5914238A (en) * 1996-06-05 1999-06-22 Matritech, Inc. Materials and methods for detection of breast cancer
JP2001508864A (en) 1996-08-13 2001-07-03 バイオヴィジョン ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニエ コマンデット ゲゼルシャフト Method of detecting a state of an organism by measuring peptide
US6207370B1 (en) * 1997-09-02 2001-03-27 Sequenom, Inc. Diagnostics based on mass spectrometric detection of translated target polypeptides

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5538897A (en) * 1994-03-14 1996-07-23 University Of Washington Use of mass spectrometry fragmentation patterns of peptides to identify amino acid sequences in databases
US5817768A (en) * 1995-06-07 1998-10-06 The New York Blood Center, Inc. Monospecific antibodies against a subunit of fibrinogen
WO2000009562A1 (en) * 1998-08-12 2000-02-24 The New York Blood Center, Inc. Novel cleaved fragments of fibrinogen
WO2000049410A2 (en) * 1999-02-16 2000-08-24 The Government Of The United States Of America, As Represented By The Secretary Department Of Health & Human Services, The National Institutes Of Health Lcm (laser capture microdissection) for cellular protein analysis
WO2001005422A2 (en) * 1999-07-15 2001-01-25 Biomerieux Stelhys Use of a polypeptide for detecting, preventing or treating a pathological condition associated with a degenerative, neurological or autoimmune disease
WO2001075454A2 (en) * 2000-04-03 2001-10-11 Oxford Glycosciences (Uk) Ltd. Diagnosis and treatment of alzheimer's disease

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
SOBEL JOAN H ET AL: "Antipeptide monoclonal antibodies to defined fibrinogen Aalpha chain regions: Anti-Aalpha 487-498, a structural probe for fibrinogenolysis.", BLOOD, vol. 91, no. 5, 1 March 1998 (1998-03-01), pages 1590 - 1598, XP002211973, ISSN: 0006-4971 *
VAZIRI N D ET AL: "FACTOR XIII AND ITS SUBSTRATES FIBRONECTIN FIBRINOGEN AND ALPHA-2 ANTIPLASMIN IN PLASMA AND URINE OF PATIENTS WITH NEPHROSIS", JOURNAL OF LABORATORY AND CLINICAL MEDICINE, vol. 117, no. 2, 1991, pages 152 - 156, XP008007679, ISSN: 0022-2143 *
WILNER, GEORGE D. ET AL: "Immunochemical studies of human fibrinopeptide A using synthetic peptide homologues", BIOCHEMISTRY (1976), 15(6), 1209-13, 1976, XP002212292 *

Also Published As

Publication number Publication date
US6627608B2 (en) 2003-09-30
WO2002088721A2 (en) 2002-11-07
US20020161185A1 (en) 2002-10-31
AU2002257402A1 (en) 2002-11-11

Similar Documents

Publication Publication Date Title
USD652519S1 (en) Dilator
AU2002236986A1 (en) Systems, methods, and compositions for achieving closure of vascular puncture sites
AU2002238065A1 (en) Systems, methods, and compositions for achieving closure of vascular puncture sites
BRPI0712159A2 (en) amphiphilic graft polymer, and process for preparing graft polymers of
WO2002022690A3 (en) A method of forming toughened thermoset articles and toughened thermoset articles produced thereby
WO2001043649A9 (en) Method and device for use in minimally invasive approximation of muscle and other tissue
WO1998026269A3 (en) Tissue examination
AU2002307797A1 (en) Method of identifying peptides capable of binding to mhc molecules, peptides identified thereby and their uses
EP2261354A3 (en) Neisseria meningitidis antigens and compositions
WO2002066986A3 (en) Polymers functionalized with fluorescent boronate motifs
DE60232360D1 (en) Trocar with an improved piercing thorn
WO2004060278A3 (en) Methods for rapid identification of pathogens in humans and animals
EP1359714A3 (en) Method and system for determining the location of a mobile computer
EP1669382A3 (en) High solids Polyurethane-Polyurea dispersions
JP2002314573A5 (en)
EP1221472A3 (en) De-icing and anti-icing solution
EP2261240A3 (en) Biosensor compositions and methods of use
MXPA06004567A (en) Immunogenic composition and method of developing a vaccine based on portions of the hiv matrix protein.
NZ548352A (en) Immunogenic peptide carrier conjugates and methods of producing same
EP1070739A3 (en) Polymer-pigment composites
WO2004041348A3 (en) Apparatus and method for pattern delivery of radiation and biological characteristic analysis
EP2269632A3 (en) Immunostimulatory compositions and methods of stimulating an immune response
WO2003053510A3 (en) Apparatus and method for multi-site anti-tachycardia pacing
EP1494427A3 (en) Signature extraction system and method
CA2400987A1 (en) Interlayer film for laminated glass and laminated glass

Legal Events

Date Code Title Description
AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP